Biotech Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Beth Israel Deaconess Medical Center, Boston
Molecular mechanisms of BKPC protective effects during cardiac surgery identified
November 4th, 2005
Bradykinin preconditioning improves the profile of cell survival proteins and limits apoptosis after cardioplegic arrest. Scientists writing in the journal Circulation report, "We hypothesized that preconditioning the heart with bradykinin (BK) would improve the profile of antiapoptotic proteins and inhibit myocardial apoptosis." J. Feng and colleagues of Beth Israel Deaconess Medical Center in Boston explained, "Eighteen rabbit hearts were retrogradely perfused with Krebs-Henseleit buffer (KHB). Six control hearts were perfused with KHB for 90 minutes without cardioplegia ischemia. Six hearts were arrested for 30 minutes (37 degrees C with...
Source: Biotech Law Weekly (2005-11-04)
|
